University equity in biotech spinouts

Anyone who has attended a life sciences partnering conference in the past twelve months has witnessed the same debate, often heated, sometimes unresolved. Venture capitalists argue that universities should stay in the low single digits for equity, 2% to 5%, full stop. Technology transfer directors push back: the IP took a decade of public funding to generate, and 5% does not reflect that investment. The moderators try to find middle ground. There rarely is any.

The argument will not be resolved by opinion. It can only be resolved by data. What do institutions actually take, country by country? Is there a pattern between how much they take and how many spinouts they produce? And what happens in countries that have recently changed the rules?

This article provides the benchmarks, drawing on publicly available data from technology transfer frameworks in eight countries: the United States, Switzerland, the United Kingdom, Germany, France, Belgium, Sweden, and Italy. Every figure cited refers specifically to life sciences, unless stated otherwise.

Why life sciences spinouts are different from software

One distinction matters more than any other. The equity benchmarks for a biotech or diagnostics spinout are fundamentally different from those for a software company, and any analysis that treats them as equivalent is misleading.

The UK's Independent Review of University Spin-out Companies, published in November 2023 by the Department for Science, Innovation and Technology, explicitly recommends a standard equity range of 10% to 25% for life sciences spinouts, contrasting this with 10% or less for software ventures. The USIT Guide, developed by TenU and endorsed by leading venture capital firms, adopts the same bifurcation.

The reasons are structural. A novel therapeutic requires years of preclinical testing, multiple phases of human clinical trials, and regulatory review by the EMA or FDA. According to the Tufts Center for the Study of Drug Development, the cost of bringing a new molecular entity through clinical development runs into hundreds of millions of euros. Even a diagnostic device reaching CE-IVDR clearance typically requires tens of millions. Only about 11% of compounds entering Phase I clinical trials ultimately reach the market, according to a 2025 analysis published in ScienceDirect covering 2,092 compounds across 19,927 clinical trials.

Because of this extreme capital intensity and timeline, the university's foundational IP (typically composition-of-matter patents or platform technology claims) represents the core asset of the company at inception. Without a secure, exclusive licence to this IP, the spinout has zero enterprise value. This existential dependence on university-generated intellectual property justifies a higher baseline equity stake than in software, where the barrier to entry is lower, the IP is often based on copyright or trade secrets, and the time to market is measured in months.

The emerging international consensus: 10% to 25%

The USIT Guide, published in April 2023 by TenU (a consortium of technology transfer offices from Oxford, Cambridge, Imperial, MIT, Stanford, and KU Leuven, working with leading venture capital firms including Sofinnova and Cambridge Innovation Capital), recommends a range of 10% to 25% of founding equity for life sciences spinouts.

The range is deliberately wide because the deal is a package. An institution that takes the upper end is expected to moderate its demands on royalties, clinical milestones, and sublicensing fees. An institution that accepts the lower end may negotiate higher downstream royalties on eventual drug sales. The principle is that the total economic burden on the spinout must remain investable, regardless of how the components are distributed.

Before 2023, no formal, internationally endorsed benchmark existed. Every deal was bespoke, every TTO had its own internal logic, and founders had no reference point.

The correlation between equity demands and spinout creation

In the United Kingdom, the average university equity stake in spinouts dropped from 21.5% in 2023 to a decade-low of 16.1% in 2024, according to the Spotlight on Spinouts 2025 report produced by the Royal Academy of Engineering and Beauhurst. In the same period, despite a 19% decline in the broader UK equity market, equity investment specifically targeting university spinouts rose to £2.6 billion.

This is the pattern that is reshaping technology transfer policy worldwide: institutions that reduced their equity demands saw an increase in both the number of spinouts created and the total capital invested in those spinouts. The European Spinouts Report 2025 confirms the broader trend: VC investment in European university spinouts in deep tech and life sciences reached $7.9 billion in the first three quarters of 2025, pacing to $9.1 billion by year-end, effectively doubling pre-pandemic levels. The six largest spinout exits in 2025, all exceeding $1 billion, came from institutions in Switzerland, the UK, and Germany, precisely the countries that have most aggressively reformed their equity models.

Country by country: what institutions actually take

United States: 1-5% equity, compensated by royalties

American universities typically take between 1% and 5% of founding equity. Stanford, Columbia, and MIT all operate in this range. The headline number is dramatically lower than Europe, but the economics are not as different as they appear. US institutions compensate with royalty structures, milestone payments, and anti-dilution provisions that maintain their percentage through the Series A round.

According to Stanford's Office of Technology Licensing policy, when the university receives equity for a licence, 15% of the total equity is classified as an "Administrative Share" allocated to the OTL for operational costs, while the remaining 85% is distributed among inventors, departments, and fellowship funds. In fiscal year 2025, Stanford's OTL generated over $88 million in licensing revenue, according to Stanford Facts.

The AUTM 2024 Licensing Activity Survey reveals a significant structural shift in how US universities capture value: gross licensing income fell by 24% and running royalties declined by 41%, while revenue from equity cash-outs rose by 25%. American institutions are increasingly trading the long-term promise of royalties for the more immediate liquidity of equity exits.

Switzerland: 2% equity, six weeks, no negotiation

ETH Zurich, under its updated Business Creation Regulations (RSETHZ 440.5), takes a nominal 2% equity stake in spinoffs that use university IP. For ventures that do not rely on ETH research results, the university takes nothing.

In 2025, ETH introduced an Express Licensing procedure: standardised terms, fixed equity, predefined fees, completed in six to eight weeks with no negotiation. According to ETH Zurich's own reporting, spinoffs raised 540 million Swiss francs across 41 financing rounds in 2025, a 27% increase from the prior year.

United Kingdom: the fastest reform in Europe

Oxford reformed in September 2021, moving from a 50/50 split to a baseline where founding researchers receive 80% of equity and the university retains 20%. According to the University of Cambridge Institute for Manufacturing's comparative analysis, in cases with less direct institutional support the split moves to 90/10.

Imperial College London introduced Founders Choice. Under the founder-driven route, as documented in its public framework guidelines, Imperial takes 5% non-dilutable equity up to £20 million in cumulative external investment for pharmaceutical spinouts, structured as "T Ordinary" shares. Royalties are capped at 0.5% for low-margin businesses and 2.0% for pharmaceutical assets. Under the jointly-driven route, the starting position is 20% dilutable.

According to the Beauhurst Spotlight on Spinouts data, Cambridge has generated 36% more successful exits than Oxford despite producing fewer spinouts. The difference in average equity demands between the two institutions is difficult to dismiss as coincidence.

Germany: 10% dilutable, plus milestone payments

The Max Planck Society, through Max Planck Innovation, takes a flat 10% dilutable equity stake. According to its published framework conditions, this stake "dilutes in the same manner as the shares of the founders during subsequent financing rounds." The licence includes market-standard fees and clinical milestone payments.

According to the European Spinouts Report 2025, Max Planck ranks second among Europe's top 20 research organisations for deep tech and life science spinoffs, with four unicorns and a combined portfolio valuation exceeding $67 billion.

France: co-investment rather than extraction

According to CNRS Innovation's published materials, the institution calibrates its equity stake based on a quantitative valuation of the incubation support provided, explicitly stating that its objective is not to become a majority shareholder. Inserm Transfert operates a dedicated seed-stage venture fund that invests directly in its own spinoffs. Inserm holds a portfolio of over 2,000 patents and ranks as the leading European academic institute for biomedical patent applications.

The French model is reinforced by massive sovereign capital deployment through the Tibi Initiative (over €20 billion committed to French VC and growth funds, targeting €30 billion by 2030) and Bpifrance.

Belgium: the venture builder model

VIB functions as a venture builder rather than a traditional TTO: founding companies, recruiting CEOs, structuring cap tables. According to the European Spinouts Report 2025, VIB has founded over 40 spinoffs that collectively raised nearly €2 billion and generated acquisitions totalling €4.5 billion.

KU Leuven Research & Development distributes exit proceeds with radical transparency: 40% directly to founding scientists, 55% to the originating research group and LRD management, 5% to the university's patent fund.

Sweden: the researcher owns 100%

Under the Lärarundantaget (Professor's Privilege), Swedish academic researchers own all intellectual property generated from their scientific work. The university has no automatic claim. If the Karolinska Institutet wants to participate in a spinout's upside, it must secure the researcher's explicit voluntary agreement.

This maximises founder equity but shifts the entire burden of IP management, patent prosecution, and venture capital negotiation onto the individual researcher.

Italy: the country that just changed the rules

Until August 2023, Italy operated under the same principle as Sweden. The Professor's Privilege, introduced in Italian law in 2001 as part of Article 65 of the Industrial Property Code, gave researchers full ownership of any IP generated during their employment at universities, IRCCS research hospitals, and public research organisations.

The result, over two decades, was not what the legislator intended. According to an analysis published in Managing Intellectual Property, researchers showed limited interest in filing patent applications under their own name. Most preferred to reach informal agreements with their universities or with the companies funding their research. The Professor's Privilege, in practice, created a system where a large volume of commercially viable IP simply never entered the technology transfer pipeline.

Law no. 102 of 24 July 2023, which entered into force on 23 August 2023, reversed the paradigm entirely. IP ownership now vests in the institution (the university, IRCCS, or public research organisation) rather than the individual researcher. The researcher retains the right to a minimum of 50% of the economic proceeds from exploitation of the invention, after deducting the costs of patent filing and maintenance. If the institution fails to file a patent application within six months (extendable to nine), the rights revert to the inventor.

This reform is still in its early phase of implementation. Some Italian TTOs, particularly those attached to the larger IRCCS networks and to universities with established industry partnerships, have years of experience negotiating licensing agreements and managing equity positions, and are well positioned to define competitive frameworks quickly. Others, especially smaller universities and research organisations with limited technology transfer infrastructure, are building these capabilities for the first time.

The opportunity is significant. Italy has 51 IRCCS research hospitals, over 100 public research laboratories, and a strong foundation in oncology, genomics, and advanced therapies. The volume of life sciences spinouts from Italian institutions could increase substantially as the new framework matures. How each institution defines its equity model, royalty structure, and speed of execution will determine whether it attracts venture capital or loses its best researchers to institutions with more investable terms.

The Italian reform is the most recent natural experiment in European technology transfer, and its outcomes over the next few years will add a significant data point to the global picture.

What this means in practice

In many countries, the equity terms are set by institutional policy and are not easily negotiated by individual researchers. The Professor's Privilege in Sweden is the exception. In most European systems, including now Italy, the TTO holds the IP and sets the terms.

Three things have changed the landscape:

First, the benchmarks are now public. The USIT Guide, the NVCA-AUTM term sheet, and the ETH Express Licence are all available online. A researcher or TTO manager who understands the international landscape is in a fundamentally different position from one who does not.

Second, the competitive pressure between institutions is real. When ETH offers 2% and six weeks, a neighbouring institution demanding 25% and twelve months of negotiation faces a direct comparison.

Third, the venture capital community is specific about what it considers an investable cap table for a life sciences company. Any structure where the institution holds more than 25% at founding will trigger scrutiny. These are not preferences. They are the mathematical constraints of a sector where the company may need five or six rounds of financing before generating a single euro of revenue.

Frequently asked questions